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INTRODUCTION
Hepatocellular carcinoma (HCC) is among the twelve 
commonest cancers affecting mankind.1 In tropical 
Africa HCC is the most common malignant tumour, 
particularly among men. In Kyadondo County of 
Uganda the incidence rate is 5,1 cases per 100 000 men. 
In Nigeria the figure quoted for both sexes is 5,9 per 100 
000 population. In Zimbabwe the incidence among the 
Black population is 20,8 per 100 000, while in Mozam­
bique the figure is 103,8 per 100 000 males. These 
figures are in contradiction to what is observed in 
Europe and North America. In England HCC occurs in 
2,5 per 100 000, while in North America it is seen in 1,8 
per 100 000.
In Africa I ICC attacks young men with a peak 
incidence at 35 years (i.e. two to three decades younger
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than in Europe and North America. The disease runs a 
fulminant downhill course with over 90 pc of untreated 
patients being dead within one month of diagnosis.2
In Africa, HCC is superimposed upon pre-existing 
post-hepatic macronodular cirrhosis in about 80 to 90 pc 
of cases. Surgical resection is seldom possible because 
of extensive disease with multifocal lesions and con­
comitant cirrhosis.
The use of systemic chemotherapy has generally 
been disappointing. The very high response rate in a 
preliminary phase II trial of Doxorubicin in Uganda in 
1975 was welcome.3 Subsequent overall response of 44 
pc was observed in a group of 50 patients with 10 pc 
achieving complete response.4 Studies in odter centres 
confirmed die Uganda experience.5 6-7-8 In Zambia ob­
jective response was observed only in patients given 
over 60 mg/m2 of Doxorubicin aldiough cardiotoxicity 
was the limiting factor.* Tsega in Ethiopia failed to 
show beneficial effects of Doxorubicin in HCC pa­
tients.9
M ore recently a Doxorubicin analogue 4- 
epidoxorubicin (Epirubicir.) has been shown to be 
active in HCC.1011 The studies suggested that it has a 
similar anti-tumour activity but with less toxicity than 
its parent compound Doxorubicin.
The aim of this study was to assess the usefulness of 
Epirubicin in African HCC and compare its effective­
ness with that of its parent compound Doxorubicin as 
well as determining the optimal doses for both com­
pounds in the treatment of African I ICC.
MATERIALS AND METHODS
Eligibility criteria: Patients aged up to 70 years with 
histologically proven hepatocellular carcinoma were 
eligible for inclusion in this study. A Karnofsky perfor­
mance status of at least 30 pc was required. Criteria for 
exclusion included previous or current cardiac pathol­
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presence of brain metastases or a second malignancy. 
Prior to entry patients were required to have adequate 
hepatic excretory function (serum bilirubin <50 umol/ 
litre) and bone marrow reserve (WBC <3,000/mm3, 
platelet count >75,000/m3).
Therapeutic regimes: Patients were stratified by 
institution and randomized to receive either Doxorubi­
cin or Epirubicin at three different dose levels. The 
doses for Doxorubicin were Doxo I (60 mg/m2) Doxo 
2 (75 mg/m2), Doxo 3 (90 mg/in2) and for Epirubicin, 
Epi I (75 mg/m2), Epi 2 (90 mg/m2) and Epi 3 (105 mg/ 
m2). Both drugs were given as an IV  bolus injection. 
Treatments were repeated every three weeks. Dose 
reduction was applied according to standard criteria
Patients showing disease progression after two 
courses of chemotherapy were regarded as treatment 
failures and were observed until death without further 
chemotherapy. If remission or stable disease occurred, 
treatment was continued until disease progression, or 
unless prohibitive toxicity occurred, or until the maxi­
mum possible dose of Doxorubicin (550 mg/m2) and 
Epirubicin (1 000 mg/m2).
Pre-treatm ent and follow-up: Baseline studies in­
cluded a full history with special emphasis on weight 
loss, jaundice, abdominal discomfort and upper gastro­
intestinal bleeding. A complete physical examination 
was performed paying particular attention to weight 
loss, jaundice, ascites, hepatic as well as splenic size, 
tumour measurements and Kamofsky score. Complete 
blood counts, biochemical profile chest X-ray, and 
ECG were done in all cases. Echocardiography and 
radionuclide cardiac scans were performed in some 
centres. Nadir blood counts between one and two 
weeks after treatment were optional. All baseline in­
vestigations were repeated before each course of treat­
ment and at the time of discontinuation.
Definition of response: Patients were considered 
evaluable for response if they had receivd at least two 
courses of chemotherapy. The end point of study was 
death from HCC. Survival was calculated from the time 
treatment was begun. Responses were defined accord­
ing to WHO criteria.12
RESULTS
From February 1987 to February 1989, 284 patients 
were randomised into the study. A total of 50 patients 
were considered ineligible due to inadequate histology 
(15 patients) and performance status <30 pc (35 pa­
tients). Among the 234 eligible patients who were 
entered (Table I), 35 patients were too early to evaluate. 
Forty three patients were not evaluable because of early 
death (40 cases) and treatment refusal (three cases).
Table I: Case series. *
Doxorubicin Epirubicin Total
Entered 120 114 234
Too early 15 20 35
Not evaluable 25 18 43
Evaluable 80 76 156
'Excluding 50 ineligible patients
One hundred and fifty six patients were fully evaluable 
with 80 receiving Doxorubicin and 76 receiving 
Epirubicin. These two groups were comparable with 
regard to age, sex, performance status disease stage, 
hepatitis B status, histological typing and biochemical 
test. Doxorubicin produced one complete response and 
31 partial responses for an overall response rate of 40 
pc (Table II).
Table II: Comparative response.
Doxorubicin Epirubicin
Type of response n pc n pc
Complete response (CR) 1 1 0 0
Partial response (PR) 31 39 30 39
Complete + partial response
(CR + PR) 32 40 30 39
No change (NC) 30 37 26 34
Progressive disease (PD) 18 23 20 27
X2 (CR+ PR), p = 0,21
No change was observed in 37 pc and progressive 
disease occurred in 23 pc in this arm. Epirubicin pro­
duced no complete response in any patient and 30 
partial responses for an overall response rate of 39 pc. 
The difference in response rate is not significant 
(p=0,21). Duration of survival was identical in the two 
groups (Figure I).
Table III gives details of survival according to the 
different dose levels of Doxorubicin and Epirubicin 
and was identical in the six treatment groups. The 
median survival among responders was nine months 
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Table III: Survival according to the different dose schedules.
Product 3 Mths 3-6 Mths 7-10 Mths 11-12 Mths More than Total
EPI-1 2 6 13 3 1 25
EPI-2 3 5 11 4 0 23
EPI-3 6 4 12 5 1 28
DOXO-1 4 2 13 7 0 26
DOXO-2 4 6 10 6 2 28
DOXO-3 5 5 11 4 1 26
Total 24 28 70 29 5 156
Figure I: Survivors following treatment
Haematological toxicity encountered during the first 
two cycles of therapy is shown in Table IV.
Nadir blood counts (days 7-14 after chemotherapy) 
were available for a total of 95 patients; 47 treated with 
Doxorubicin and 48 with Epirubicin. Doxorubicin sig­
nificantly produced more haematological toxicity than 
Epirubicin. The difference between the two groups was 
highly significant (p = 0,007, chi square test for linear 
trend).
Non-haematological toxicities during the first two 
courses are shown in Table V.
Nausea and vomiting and alopecia were signifi­
cantly more frequent and pronounced in patients treated 
with Doxorubicin than in those with Epirubicin.
Table TV: Haematological toxicity. Leucocytes during 
first two cycles.
Grade Leucocytes/mm3 Doxorubicin Epirubicin
0 4 000 14 24
1 33 000-3 900 9 13
2 2 000-2 900 11 8
3-4 2 000 11 3
X2 test for linear trend, p = 0,007
Table V: Non-haematological toxicities recorded dur­
ing the first two courses
Type of Doxorubicin Epirubicin X2 for trend
toxicity (PC) (PC) p value
Nausea and
vomiting 95 76 0,05
Diarrhoea 10 7 0,5
Anorexia 47 36 0,10
Mucositis 16 10 0,20
Alopecia 38 27 0,0008
Five cases of cardia symptoms occurred in the Doxo­
rubicin arm with one patient on the 60 mg/m2, two 
patients on the 75 mg/m2 and two patients on the 90 mg/ 
m2 regimes respectively. One patient developed a grade 
two cardiac dysfunction after receiving a cumulative 
dose of 474 mg/m2. Three patients had arrthymias and 
grade four dysfunction at a dose of 550 mg/m2. One 
patient had a significant decrease of the ejection frac-
430
tion at a cumulative dose of 271 mg/m1. In theEpirubicin 
group, only one patient developed grade two dysfunc­
tion after receiving 1 000 mg/2.
DISCUSSION
The results in this study show that Epirubicin is an 
active agent in African I ICC. The overall response rate 
of Epirubicin (39 pc) was comparable to that of Doxo­
rubicin (40 pc). There were no differences in duration 
of response or survival among the two drugs or the six 
dosage levels (three for each drug) tested.
Although nadir blood counts were only available in 
95 patients (61 pc) it was apparent that Doxorubicin 
was significantly more toxic than Epirubicin and that 
this was also the case for occurrence of nausea and 
vomiting as well as alopecia. Cardiac toxicity was also 
more commonly seen with Doxorubicin.
It is concluded that Epirubicin is active in African 
I ICC and that its activity is equal to that of Doxorubicin 
but with less toxicity. Higher cumulative doses of the 
drug can be employed with a wider safety margin. Thus 
more cycles of chemotherapy can be administered 
either for response maintenance or palliative purposes.
With regard to Doxorubicin we have firmly estab­
lished that the optimal dose is 60 ing/m2 as there is no 
increased benefit with higher doses of the drug and yet 
one runs the risk of increased toxicity with higher 
doses. The results open up the possibility of a more 
aggressive treatment with higher doses of Epirubicin 
which might yield a higher durable incidence of clini­
cal remission or prolonged survival.
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